Chronic Kidney DiseasePhase 1NCT07694544
Renal Impairment Study for Oral EC5026
A Phase 1 study testing EC5026 oral tablet in people with Chronic Kidney Disease, run by EicOsis Human Health Inc. at 1 site in United States.
Trial summary
The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 55 years and olderHealthy volunteers can take part
- Conditions the study is for
- Chronic Kidney Disease
- What is being tested?
- EC5026 oral tablet
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2026to 30 Jun 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Each study participant must meet all of the following criteria to be enrolled in this study:
- Male and female participants must be 55 and older.
- Study participants must be willing and able to provide written informed consent to participate in the study.
- Participants with CKD must be stage 3b-5 (estimated glomerular filtration rate (eGFR) ≤ 44 ml/min per 1.73m2) without dialysis. Control participants must have an eGFR of ≥90 ml/min per 1.73m2.
- Aside from the diagnosis of CKD, study participants must be in overall stable condition, as determined by pre-study medical history, physical examination, clinical laboratory tests, and 12-lead ECG measurements.
- Study participants must have a body mass index (BMI) of 19-40 kg/m2. Participants with a BMI below 19 kg/m2 may be enrolled at the Investigator's discretion.
Show all 12Show fewer
- Study participants must have a systolic blood pressure (BP) of 90-170 mmHg, diastolic BP of 50-90 mmHg, and resting HR of 40-100 beats per min at Screening, with or without stable doses of anti-hypertensive medication.
- Study participants must be non-smokers or previous smokers who have not smoked within the previous 6 months prior to Screening.
- Participants taking non-study medications not explicitly listed in the exclusion criteria must be on stable doses of medications for at least 30 days prior to enrollment. Doses should be expected to remain stable for the duration of the study. Standard of care medications for the CKD population which will be allowed at stable doses include, but are not limited to: beta blockers, dihydropyridine calcium channel blockers (i.e. amlodipine), ACE-inhibitors (i.e. lisinopril), ARB (i.e. losartan, valsartan), aspirin, statins, SGLT2 inhibitor (empagliflozin, dapagliflozin), GLP1-RA or GLP-RA/GIP (i.e. semaglutide, tirzepatide), warfarin, direct-acting oral anticoagulants (DOACs - apixaban, rivaroxaban), clopidogrel, and ticagrelor. Study participants taking non-study medications will be included at the opinion of the Investigator and Medical monitor.
- Male participants must not donate sperm during the study and for 12 months after receiving the last dose of study drug.
- Male participants must use, from enrollment until at least 2 months after the last dose, a highly effective contraception method (less than 1 pregnancy per 100 people using the method for one year), e.g.: sterilization (e.g., vasectomy), and/or double barrier forms of contraception, including condoms (external or internal) and diaphragm ('cap').
- Female participants must be non-pregnant, non-lactating, and either postmenopausal for at least 1 year, or surgically sterile (bilateral tubal ligation ('clipping or tying tubes' or hysterectomy) for at least 3 months, or they must agree to use a highly effective double barrier contraception method (less than 1 pregnancy per 100 people using the method for one year), from 28 days and/or their last confirmed menstrual period prior to study enrollment (whichever is longer) until 2 months after the end of study. Postmenopausal status will be defined as follows: documented postmenopausal status as determined by a physician in medical record at least 1 year prior or amenorrhea duration of 12 consecutive months and a serum FSH value >40 IU/L (postmenopausal status must be confirmed at Screening). Highly effective double barrier contraception methods include: Intra-uterine device containing either copper or levonorgestrel (e.g., Mirena®), and/or barrier methods of contraception, including condoms (external or internal) and diaphragm ('cap'). Participants/Participant's partner(s) must also use a barrier form of contraception, from the first dose of study drug through until 2 months after the last dose. For all females of childbearing potential, the pregnancy test result must be negative prior to dosing.
Who cannot join
- Study participants meeting any of the following criteria will be excluded from the study:
- Participants who have donated and/or received any blood or blood products (more than 450 mL) within 3 months prior to enrollment.
- Participants who have used any other investigational drug within 1 month prior to Screening. If the investigational drug is known to have a long half-life, a longer washout period will be done.
- Participants using opioid medications on a regular basis or pro re nata (PRN). Non-opioid pain medications will be allowed if at a fixed stable dose for more than 1 month prior to Screening with no anticipation of the dose changing during the study. Allowed non-opioid medications include gabapentin, pregabalin, duloxetine, acetaminophen, ibuprofen, celecoxib, meloxicam, other antidepressants including amitriptyline, and other antiepileptics, as well as topical capsaicin and topical lidocaine.
- Participants who have used (within 30 days of enrollment) or plan on using during the duration of the study any prescription or over-the-counter drugs that are cytochrome P450 3A4 (CYP3A4) inducers or inhibitors (e.g., verapamil, diltiazem, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, cimetidine, paroxetine, fluoxetine, haloperidol, ketoconazole, itraconazole, fluconazole, erythromycin, or clarithromycin).
- Participants who have used (within 30 days of enrollment) or plan on using during the duration of the study any dietary aids, supplements, or foods that are known to modulate drug metabolizing enzymes (e.g., St. John's wort, grapefruit juice).
Show all 23Show fewer
- Participants with difficulty in swallowing oral medications.
- Participants who have active cancer or have a high risk of cancer recurrence requiring active surveillance. Participants with a personal history of cancer or metastatic cancer in first degree relatives suggestive of elevated cancer risk in the opinion of the investigator.
- Participants with a history of disorders of the hypothalamic-pituitary-adrenal or hypothalamic-pituitary-gonadal axis
- Participants with a presence or history of active gastrointestinal disorder, including esophageal or gastroduodenal ulceration, or hepatic, or coagulant disorder within 1 month prior to enrollment
- Participants with any clinically unstable cardiovascular (including acute coronary syndrome within the 6 months prior to Screening), respiratory, hematological, endocrine disorder, as determined by the study physician.
- Participants with severe systolic heart failure (Ejection Fraction <35%).
- Participants with exercise-limiting cardiopulmonary disease including severe valvular heart disease, exertional angina, and/or major atherosclerotic cardiovascular event within last 6 months.
- Participants with a history of unstable arrhythmia.
- Participants with clinically significant and persistent electrolyte abnormalities including hypokalemia (K<3.4mEq/dL) or hyperkalemia (K>5.4mEq/dL).
- Participants with serious psychosocial comorbidities as determined by the Investigator.
- Participants with current cognitive or major psychiatric disorders, or any other condition that could interfere with compliance with study procedures.
- Participants with a history of bacterial, fungal, or viral infection requiring treatment with antibiotics, antifungal agents, or antivirals within 1 month prior to enrollment.
- Participants with confirmed COVID-19, or suspected COVID-19 (e.g., developed symptoms of a respiratory infection such as cough, sore throat, shortness of breath, or fever, but did not get tested for COVID-19) at the time of screening.
- Participants with confirmed moderate-severe COVID-19 within 2 months of enrollment or with confirmed asymptomatic or mild COVID-19 within 4 weeks of enrollment.
- Participants who have received a COVID-19 vaccine within 4 weeks of enrollment or are planning on receiving it during the study duration.
- Participants with medical history of active Hepatitis A, Hepatitis B, Hepatitis C, and/or HIV.
- Participants with a positive drug or alcohol test during Screening and/or admission (a positive THC test will be allowed as long as it consists of minimal social use, per discretion of Investigator).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UC Davis Medical Center
Sacramento, California, 95817
Jennifer Norman Project Scientist, jenorman@health.ucdavis.edu
Baback Roshanravan, MD
About this study
Official title: Assessment of Single Dose Pharmacokinetics of Oral EC5026 in a Population With Chronic Kidney Disease
The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are:
- To determine if the PK of a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD differs from age-matched healthy participants with normal kidney function.
- To determine if a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD is safe and well tolerated.
Read more
Researchers will compare a single 8 mg dose of oral across participants with varying degrees of kidney function impairment (either normal kidney function, or stage 3b chronic kidney disease [CKD], or state 4/5 CKD).
Participants will be asked to take a single oral dose of EC5026 and will be monitored with PK laboratory assessments and safety assessments (including physical exams, vital signs, electrocardiograms, and others).
- Conditions
- Chronic Kidney Disease
- Being tested
- EC5026 oral tablet
- Keywords
- Renal impairment study, EC5026, sEH inhibitor, Chronic kidney disease (CKD)
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EC5026 oral tabletDrug
Oral 8 mg EC5026 tablet
| Study group | Role | What they receive |
|---|---|---|
| Control Arm | Experimental | Participants with normal kidney function receiving a single 8 mg oral dose of EC5026 Receives: Drug: EC5026 oral tablet |
| CKD Stage 3b | Experimental | Participants with CKD Stage 3b receiving a single 8 mg oral dose of EC5026 Receives: Drug: EC5026 oral tablet |
| CKD Stage 4/5 (non dialysis) | Experimental | Participants with CKD Stages 4/5 (non dialysis) receiving a single 8 mg oral dose of EC5026 Receives: Drug: EC5026 oral tablet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t)
The area under the plasma concentration-time curve from dosing until the last measurable concentration. Plasma concentrations will be measured from blood samples collected at prespecified time points (0, 2, 4, 6, 8, 24 hours, and 3, 5, 7, 14 days after administration) using a validated bioanalytical assay. AUC0-t will be calculated using noncompartmental pharmacokinetic methods and represents systemic exposure to the study drug over the measured sampling interval.
Measured: 14 days
Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)
The area under the plasma concentration-time curve from dosing extrapolated to infinite time. Plasma concentrations will be measured from blood samples collected at prespecified time points (see above) using a validated bioanalytical assay. AUC0-∞ will be calculated using noncompartmental pharmacokinetic methods and represents the total systemic exposure to the study drug.
Measured: 14 days
Maximum observed plasma concentration (Cmax)
The highest observed plasma concentration of the study drug following administration. Plasma concentrations will be measured from blood samples collected at prespecified time points (see above) using a validated bioanalytical assay.
Measured: 14 days
Time to the maximum observed concentration of the drug (Tmax)
The time from study drug administration to the maximum observed plasma concentration (Cmax). Tmax will be determined directly from the observed plasma concentration-time data.
Measured: 14 days
Apparent terminal elimination rate constant (Kel)
The apparent rate at which the study drug is eliminated from plasma during the terminal phase after administration. Kel will be estimated from the terminal log-linear portion of the plasma concentration-time curve using noncompartmental pharmacokinetic methods.
Measured: 14 days
Terminal elimination half-life of the drug (t½).
The time required for the plasma concentration of the study drug to decrease by 50% during the terminal elimination phase. Half-life will be estimated from the terminal elimination rate constant using noncompartmental pharmacokinetic methods.
Measured: 14 days
Apparent clearance (CL/F).
The apparent volume of plasma from which the study drug is removed per unit time following oral administration, accounting for unknown oral bioavailability (F). Apparent clearance will be estimated using noncompartmental pharmacokinetic methods.
Measured: 14 days
Apparent volume of distribution during the terminal phase (Vz/F)
The apparent volume into which the study drug distributes during the terminal elimination phase following oral administration, accounting for unknown oral bioavailability (F). This parameter will be estimated using noncompartmental pharmacokinetic methods.
Measured: 14 days
Renal clearance (CLR)
The apparent volume of plasma from which unchanged study drug is removed by the kidneys per unit time. Renal clearance will be calculated using plasma concentration and urine excretion data collected over prespecified sampling intervals.
Measured: 48 hours
Amount of unchanged drug excreted in urine (Ae).
The cumulative amount of unchanged study drug recovered in urine following study drug administration. Urine samples will be collected over prespecified time intervals and analyzed using a validated bioanalytical assay.
Measured: 48 hours
Fraction of eliminated dose (Fe%)
The percentage of the administered study drug dose recovered unchanged in urine over the specified collection period. Fe% will be calculated from the cumulative amount of unchanged drug excreted in urine relative to the administered dose.
Measured: 48 hours
Secondary outcomes (7)
Incidence, intensity, relationship, and seriousness of treatment-emergent adverse events (TEAEs)
Treatment-emergent adverse events are adverse events that begin or worsen after administration of study drug. Adverse events will be assessed throughout the study and summarized by incidence, intensity (severity), relationship to study drug as determined by the investigator, and seriousness. Adverse events will be coded using the current version of the Medical Dictionary for Regulatory Activities (MedDRA).
Measured: 14 days
Treatment-emergent changes in vital signs
Vital signs, including systolic and diastolic blood pressure, heart rate, respiratory rate, body temperature, and body weight, will be measured at prespecified study visits. Treatment-emergent changes from baseline and clinically significant abnormalities will be summarized.
Measured: 14 days
Treatment-emergent changes in hematology laboratory parameters
Hematology laboratory assessments, including complete blood count and differential, will be performed at prespecified study visits. Treatment-emergent changes from baseline and clinically significant laboratory abnormalities will be summarized.
Measured: 14 days
Treatment-emergent changes in serum chemistry laboratory parameters
Serum chemistry laboratory assessments, including electrolytes, liver function tests, glucose, and other serum chemistry analytes, will be performed at prespecified study visits. Treatment-emergent changes from baseline and clinically significant laboratory abnormalities will be summarized.
Measured: 14 days
Treatment-emergent changes in renal function assessments
Renal function will be assessed using serum creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), and urinary albumin-to-creatinine ratio (uACR). Treatment-emergent changes from baseline and clinically significant abnormalities will be summarized.
Measured: 14 days
Treatment-emergent changes in 12-lead electrocardiograms (ECGs)
Standard 12-lead electrocardiograms will be obtained at prespecified study visits. Treatment-emergent changes from baseline and clinically significant ECG abnormalities, including heart rate, rhythm, conduction intervals, and morphology, will be summarized.
Measured: 14 days
Treatment-emergent changes in physical examinations findings
Physical examinations will be performed at prespecified study visits. Treatment-emergent clinically significant changes from baseline will be summarized.
Measured: 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2026
- Study start1 Jul 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 18 participants (estimated)
Sponsor and investigators
- Lead sponsor
- EicOsis Human Health Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07694544
- Sponsor's protocol ID
- EC5026-1-06
- Status last verified
- Jul 2026
- First submitted
- 3 Jul 2026
- Last updated
- 10 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Single Dose Pharmacokinetics of Oral EC5026 in a Population With Chronic Kidney Disease
- ClinicalTrials.gov ID
- NCT07694544
- Acronym / sponsor ID
- EC5026-1-06
- Conditions
- Chronic Kidney Disease
- Keywords
- Renal impairment study, EC5026, sEH inhibitor, Chronic kidney disease (CKD)
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 18 participants (estimated)
- Lead sponsor
- EicOsis Human Health Inc.Industry (pharma, biotech, devices)
- Study start
- 1 Jul 2026 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 10 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are:
- To determine if the PK of a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD differs from age-matched healthy participants with normal kidney function.
- To determine if a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD is safe and well tolerated.
Researchers will compare a single 8 mg dose of oral across participants with varying degrees of kidney function impairment (either normal kidney function, or stage 3b chronic kidney disease [CKD], or state 4/5 CKD).
Participants will be asked to take a single oral dose of EC5026 and will be monitored with PK laboratory assessments and safety assessments (including physical exams, vital signs, electrocardiograms, and others).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control Arm | Experimental | Drug: EC5026 oral tabletParticipants with normal kidney function receiving a single 8 mg oral dose of EC5026 |
| CKD Stage 3b | Experimental | Drug: EC5026 oral tabletParticipants with CKD Stage 3b receiving a single 8 mg oral dose of EC5026 |
| CKD Stage 4/5 (non dialysis) | Experimental | Drug: EC5026 oral tabletParticipants with CKD Stages 4/5 (non dialysis) receiving a single 8 mg oral dose of EC5026 |
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Each study participant must meet all of the following criteria to be enrolled in this study:
- Male and female participants must be 55 and older.
- Study participants must be willing and able to provide written informed consent to participate in the study.
- Participants with CKD must be stage 3b-5 (estimated glomerular filtration rate (eGFR) ≤ 44 ml/min per 1.73m2) without dialysis. Control participants must have an eGFR of ≥90 ml/min per 1.73m2.
- Aside from the diagnosis of CKD, study participants must be in overall stable condition, as determined by pre-study medical history, physical examination, clinical laboratory tests, and 12-lead ECG measurements.
Key exclusion criteria (23 listed)
- Participants who have donated and/or received any blood or blood products (more than 450 mL) within 3 months prior to enrollment.
- Participants who have used any other investigational drug within 1 month prior to Screening. If the investigational drug is known to have a long half-life, a longer washout period will be done.
- Participants using opioid medications on a regular basis or pro re nata (PRN). Non-opioid pain medications will be allowed if at a fixed stable dose for more than 1 month prior to Screening with no anticipation of the dose changing during the study. Allowed non-opioid medications include gabapentin, pregabalin, duloxetine, acetaminophen, ibuprofen, celecoxib, meloxicam, other antidepressants including amitriptyline, and other antiepileptics, as well as topical capsaicin and topical lidocaine.
- Participants who have used (within 30 days of enrollment) or plan on using during the duration of the study any prescription or over-the-counter drugs that are cytochrome P450 3A4 (CYP3A4) inducers or inhibitors (e.g., verapamil, diltiazem, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, cimetidine, paroxetine, fluoxetine, haloperidol, ketoconazole, itraconazole, fluconazole, erythromycin, or clarithromycin).
- Participants who have used (within 30 days of enrollment) or plan on using during the duration of the study any dietary aids, supplements, or foods that are known to modulate drug metabolizing enzymes (e.g., St. John's wort, grapefruit juice).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EC5026 oral tabletOral 8 mg EC5026 tablet | Drug | CKD Stage 3b, CKD Stage 4/5 (non dialysis), Control Arm |
Primary outcome
Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t)
Time frame: 14 days
The area under the plasma concentration-time curve from dosing until the last measurable concentration. Plasma concentrations will be measured from blood samples collected at prespecified time points (0, 2, 4, 6, 8, 24 hours, and 3, 5, 7, 14 days after administration) using a validated bioanalytical assay. AUC0-t will be calculated using noncompartmental pharmacokinetic methods and represents systemic exposure to the study drug over the measured sampling interval.
Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)
Time frame: 14 days
The area under the plasma concentration-time curve from dosing extrapolated to infinite time. Plasma concentrations will be measured from blood samples collected at prespecified time points (see above) using a validated bioanalytical assay. AUC0-∞ will be calculated using noncompartmental pharmacokinetic methods and represents the total systemic exposure to the study drug.
Maximum observed plasma concentration (Cmax)
Time frame: 14 days
The highest observed plasma concentration of the study drug following administration. Plasma concentrations will be measured from blood samples collected at prespecified time points (see above) using a validated bioanalytical assay.
Time to the maximum observed concentration of the drug (Tmax)
Time frame: 14 days
The time from study drug administration to the maximum observed plasma concentration (Cmax). Tmax will be determined directly from the observed plasma concentration-time data.
Apparent terminal elimination rate constant (Kel)
Time frame: 14 days
The apparent rate at which the study drug is eliminated from plasma during the terminal phase after administration. Kel will be estimated from the terminal log-linear portion of the plasma concentration-time curve using noncompartmental pharmacokinetic methods.
Terminal elimination half-life of the drug (t½).
Time frame: 14 days
The time required for the plasma concentration of the study drug to decrease by 50% during the terminal elimination phase. Half-life will be estimated from the terminal elimination rate constant using noncompartmental pharmacokinetic methods.
Apparent clearance (CL/F).
Time frame: 14 days
The apparent volume of plasma from which the study drug is removed per unit time following oral administration, accounting for unknown oral bioavailability (F). Apparent clearance will be estimated using noncompartmental pharmacokinetic methods.
Apparent volume of distribution during the terminal phase (Vz/F)
Time frame: 14 days
The apparent volume into which the study drug distributes during the terminal elimination phase following oral administration, accounting for unknown oral bioavailability (F). This parameter will be estimated using noncompartmental pharmacokinetic methods.
Renal clearance (CLR)
Time frame: 48 hours
The apparent volume of plasma from which unchanged study drug is removed by the kidneys per unit time. Renal clearance will be calculated using plasma concentration and urine excretion data collected over prespecified sampling intervals.
Amount of unchanged drug excreted in urine (Ae).
Time frame: 48 hours
The cumulative amount of unchanged study drug recovered in urine following study drug administration. Urine samples will be collected over prespecified time intervals and analyzed using a validated bioanalytical assay.
Fraction of eliminated dose (Fe%)
Time frame: 48 hours
The percentage of the administered study drug dose recovered unchanged in urine over the specified collection period. Fe% will be calculated from the cumulative amount of unchanged drug excreted in urine relative to the administered dose.
7 secondary outcomes
Incidence, intensity, relationship, and seriousness of treatment-emergent adverse events (TEAEs)
Time frame: 14 days
Treatment-emergent changes in vital signs
Time frame: 14 days
Treatment-emergent changes in hematology laboratory parameters
Time frame: 14 days
Treatment-emergent changes in serum chemistry laboratory parameters
Time frame: 14 days
Treatment-emergent changes in renal function assessments
Time frame: 14 days
Treatment-emergent changes in 12-lead electrocardiograms (ECGs)
Time frame: 14 days
Treatment-emergent changes in physical examinations findings
Time frame: 14 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Chronic Kidney Disease
RecruitingPhase 2
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
Chronic Kidney Disease
Active, not recruitingPhase 4
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
Chronic Kidney Disease
Recruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Fluid Accumulation, Blood Pressure Management
Active, not recruitingPhase 2
Management of Iron Deficiency Anemia in Hemodialysis Patients
Iron Deficiency Anemia (IDA), ESRD (End Stage Renal Disease)
Not yet recruiting
Combined Versus Multicomponent Training in People With Chronic Kidney Disease Stages 3a and 3b
Chronic Kidney Disease Stage 3A, Chronic Kidney Disease Stage 3B
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing EC5026 oral tablet in people with Chronic Kidney Disease, run by EicOsis Human Health Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact EicOsis Senior Clinical Scientist (301-821-5857, icortespuch@eicosis.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t) (time frame: 14 days). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026; AzTrials last refreshed its copy on 31 Oct 2026.